{"id":"https://openalex.org/W7214928962","doi":"https://doi.org/10.3389/fendo.2026.1939938","title":"Efficacy and safety of bevacizumab plus XELOX in patients with unresectable locally advanced or metastatic neuroendocrine tumors","display_name":"Efficacy and safety of bevacizumab plus XELOX in patients with unresectable locally advanced or metastatic neuroendocrine tumors","publication_year":2026,"publication_date":"2026-09-30","ids":{"openalex":"https://openalex.org/W7214928962","doi":"https://doi.org/10.3389/fendo.2026.1939938","pmid":"https://pubmed.ncbi.nlm.nih.gov/42876479","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13661408"},"language":"en","primary_location":{"id":"doi:10.3389/fendo.2026.1939938","doi":"https://doi.org/10.3389/fendo.2026.1939938","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fendo.2026.1939938","pdf_url":"https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1939938/pdf","source":{"id":"https://openalex.org/S2597401208","display_name":"Frontiers in Endocrinology","issn_l":"1664-2392","issn":["1664-2392"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Endocrinology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1939938/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5139369060","display_name":"Huike Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I200296433","display_name":"Chinese Academy of Medical Sciences & Peking Union Medical College","ror":"https://ror.org/02drdmm93","country_code":"CN","type":"education","lineage":["https://openalex.org/I200296433"]},{"id":"https://openalex.org/I4210141458","display_name":"Cancer Hospital of Chinese Academy of Medical Sciences","ror":"https://ror.org/03x937183","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210141458"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Huike Wang","raw_affiliation_strings":["Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","institution_ids":["https://openalex.org/I200296433","https://openalex.org/I4210141458"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5153604560","display_name":"Huijing Tan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I200296433","display_name":"Chinese Academy of Medical Sciences & Peking Union Medical College","ror":"https://ror.org/02drdmm93","country_code":"CN","type":"education","lineage":["https://openalex.org/I200296433"]},{"id":"https://openalex.org/I4210141458","display_name":"Cancer Hospital of Chinese Academy of Medical Sciences","ror":"https://ror.org/03x937183","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210141458"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Huijing Tan","raw_affiliation_strings":["Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","institution_ids":["https://openalex.org/I200296433","https://openalex.org/I4210141458"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5146841362","display_name":"Yuting Sun","orcid":"https://orcid.org/0000-0002-2794-869X","observed_orcids":["https://orcid.org/0000-0002-2794-869X"]},"institutions":[{"id":"https://openalex.org/I200296433","display_name":"Chinese Academy of Medical Sciences & Peking Union Medical College","ror":"https://ror.org/02drdmm93","country_code":"CN","type":"education","lineage":["https://openalex.org/I200296433"]},{"id":"https://openalex.org/I4210141458","display_name":"Cancer Hospital of Chinese Academy of Medical Sciences","ror":"https://ror.org/03x937183","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210141458"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yuting Sun","raw_affiliation_strings":["Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","institution_ids":["https://openalex.org/I200296433","https://openalex.org/I4210141458"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5153604382","display_name":"Yanwei Su","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I200296433","display_name":"Chinese Academy of Medical Sciences & Peking Union Medical College","ror":"https://ror.org/02drdmm93","country_code":"CN","type":"education","lineage":["https://openalex.org/I200296433"]},{"id":"https://openalex.org/I4210141458","display_name":"Cancer Hospital of Chinese Academy of Medical Sciences","ror":"https://ror.org/03x937183","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210141458"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yanwei Su","raw_affiliation_strings":["Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","institution_ids":["https://openalex.org/I200296433","https://openalex.org/I4210141458"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5153598524","display_name":"Yihebali Chi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I200296433","display_name":"Chinese Academy of Medical Sciences & Peking Union Medical College","ror":"https://ror.org/02drdmm93","country_code":"CN","type":"education","lineage":["https://openalex.org/I200296433"]},{"id":"https://openalex.org/I4210141458","display_name":"Cancer Hospital of Chinese Academy of Medical Sciences","ror":"https://ror.org/03x937183","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210141458"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yihebali Chi","raw_affiliation_strings":["Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","institution_ids":["https://openalex.org/I200296433","https://openalex.org/I4210141458"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.69961737,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1939938","last_page":"1939938"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neuroendocrine-tumors","display_name":"neuroendocrine tumors","score":0.9409999847412109},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9459999799728394},{"id":"https://openalex.org/keywords/xelox","display_name":"XELOX","score":0.9890000224113464},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.949999988079071},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":1.0},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.9760000109672546},{"id":"https://openalex.org/keywords/well-differentiated-neuroendocrine-tumors","display_name":"well-differentiated neuroendocrine tumors","score":0.8130000233650208},{"id":"https://openalex.org/keywords/metastatic-neuroendocrine-tumors","display_name":"metastatic neuroendocrine tumors","score":0.9039999842643738},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.8029999732971191},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8880000114440918},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9829999804496765},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.6370000243186951},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.781000018119812},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.49799999594688416}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9379000067710876},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.864799976348877},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.6933000087738037},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6808000206947327},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6531000137329102},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6485999822616577},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.6421999931335449},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.5936999917030334},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5756999850273132},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5264999866485596},{"id":"https://openalex.org/C2779066768","wikidata":"https://www.wikidata.org/wiki/Q1981276","display_name":"Neuroendocrine tumors","level":2,"score":0.5006999969482422},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4952999949455261},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.44339999556541443},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4350999891757965},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.37279999256134033},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.361299991607666},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.31630000472068787},{"id":"https://openalex.org/C2780283643","wikidata":"https://www.wikidata.org/wiki/Q2110267","display_name":"Primary tumor","level":4,"score":0.31029999256134033},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.3005000054836273},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.2978000044822693},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.2928999960422516},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2849999964237213},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.28200000524520874},{"id":"https://openalex.org/C2987315675","wikidata":"https://www.wikidata.org/wiki/Q1773974","display_name":"Disease control","level":2,"score":0.250900000333786}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010071","descriptor_name":"Oxaloacetates","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.3389/fendo.2026.1939938","doi":"https://doi.org/10.3389/fendo.2026.1939938","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fendo.2026.1939938","pdf_url":"https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1939938/pdf","source":{"id":"https://openalex.org/S2597401208","display_name":"Frontiers in Endocrinology","issn_l":"1664-2392","issn":["1664-2392"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Endocrinology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13661408","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13661408/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13661408/pdf/fendo-17-1939938.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Endocrinol (Lausanne)","raw_type":"Text"},{"id":"pmid:42876479","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42876479","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in endocrinology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:197c27e6d97e46468a26d464f222b124","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/197c27e6d97e46468a26d464f222b124","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Endocrinology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fendo.2026.1939938","doi":"https://doi.org/10.3389/fendo.2026.1939938","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fendo.2026.1939938","pdf_url":"https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1939938/pdf","source":{"id":"https://openalex.org/S2597401208","display_name":"Frontiers in Endocrinology","issn_l":"1664-2392","issn":["1664-2392"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Endocrinology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332531","display_name":"Wu Jieping Medical Foundation","ror":"https://ror.org/05dgwj702"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7214928962.pdf","grobid_xml":"https://content.openalex.org/works/W7214928962.grobid-xml"},"referenced_works_count":46,"referenced_works":["https://openalex.org/W1581678255","https://openalex.org/W1835922716","https://openalex.org/W1974766483","https://openalex.org/W1980316717","https://openalex.org/W1981584797","https://openalex.org/W1993694656","https://openalex.org/W1995681258","https://openalex.org/W2024966748","https://openalex.org/W2053262936","https://openalex.org/W2057103712","https://openalex.org/W2081457024","https://openalex.org/W2082715008","https://openalex.org/W2090232354","https://openalex.org/W2115686439","https://openalex.org/W2117668987","https://openalex.org/W2121079285","https://openalex.org/W2123731993","https://openalex.org/W2135657152","https://openalex.org/W2158474413","https://openalex.org/W2159009361","https://openalex.org/W2229261843","https://openalex.org/W2336877383","https://openalex.org/W2371508518","https://openalex.org/W2466852244","https://openalex.org/W2552824182","https://openalex.org/W2558567182","https://openalex.org/W2608160487","https://openalex.org/W2912060282","https://openalex.org/W2944761801","https://openalex.org/W3006206047","https://openalex.org/W3012964752","https://openalex.org/W3043694067","https://openalex.org/W3044434358","https://openalex.org/W3087238097","https://openalex.org/W3108245838","https://openalex.org/W3155615476","https://openalex.org/W3188272369","https://openalex.org/W3193520062","https://openalex.org/W4205179982","https://openalex.org/W4306822619","https://openalex.org/W4313250081","https://openalex.org/W4318481195","https://openalex.org/W4386705026","https://openalex.org/W4389221748","https://openalex.org/W4402332442","https://openalex.org/W4410068804"],"related_works":["https://openalex.org/W4313250081","https://openalex.org/W3204409819","https://openalex.org/W2468894750","https://openalex.org/W4224311543","https://openalex.org/W2216135087","https://openalex.org/W2169005202","https://openalex.org/W2241119392","https://openalex.org/W2371508518","https://openalex.org/W3005341553","https://openalex.org/W2895649712"],"abstract_inverted_index":{"Neuroendocrine":[0],"tumors":[1],"(NETs)":[2],"are":[3,338],"highly":[4],"vascularized":[5],"malignancies":[6],"for":[7],"which":[8],"effective":[9],"treatment":[10,98,327],"options":[11],"remain":[12],"limited":[13],"in":[14,29,157,164,170,177,181,308],"the":[15,106,137,143,201,217,276,313],"unresectable":[16,49],"locally":[17,50],"advanced":[18,30,51,309],"or":[19,52,147,325],"metastatic":[20,53],"setting.":[21],"Although":[22],"platinum-based":[23],"chemotherapy":[24,331],"has":[25],"demonstrated":[26],"antitumor":[27,301],"activity":[28,302],"NETs,":[31],"evidence":[32],"supporting":[33],"its":[34,346],"combination":[35],"with":[36,47,75,228],"antiangiogenic":[37],"therapy":[38],"remains":[39],"insufficient.":[40],"In":[41,191],"this":[42,318],"retrospective":[43,314],"study,":[44],"85":[45,198],"patients":[46,92,204],"progressive":[48,174],"well-differentiated":[54],"NETs":[55],"initiated":[56],"bevacizumab":[57,62,295],"plus":[58,296],"XELOX,":[59],"consisting":[60],"of":[61,85,184,189,214,235],"at":[63,68,77,95],"7.5":[64],"mg/kg":[65],"and":[66,100,134,173,186,231,238,246,266,270,303,315,344],"oxaliplatin":[67],"130":[69],"mg/m\u00b2":[70,79],"every":[71],"3":[72],"weeks,":[73],"together":[74],"capecitabine":[76],"1,000":[78],"twice":[80],"daily":[81],"on":[82],"days":[83],"1-14":[84],"each":[86],"21-day":[87],"cycle.":[88],"Among":[89,136],"them,":[90],"72":[91],"who":[93],"completed":[94],"least":[96],"two":[97],"cycles":[99],"underwent":[101],"post-baseline":[102],"radiological":[103],"evaluations":[104],"comprised":[105],"safety":[107,306],"set.":[108],"The":[109,251],"primary":[110],"endpoint":[111],"was":[112,208,220,243,275],"objective":[113],"response":[114,155,162],"rate":[115,126],"(ORR)":[116],"by":[117],"RECIST":[118],"v1.1,":[119],"while":[120,273],"secondary":[121],"endpoints":[122],"included":[123,153],"disease":[124,168,175],"control":[125],"(DCR),":[127],"progression-free":[128],"survival":[129,132],"(PFS),":[130],"overall":[131],"(OS),":[133],"safety.":[135],"efficacy-evaluable":[138],"patients,":[139],"62":[140],"(86.1%)":[141],"received":[142],"regimen":[144,319],"as":[145,205],"second-line":[146],"later":[148],"systemic":[149],"therapy.":[150],"Best":[151],"responses":[152],"complete":[154],"(CR)":[156],"1":[158,178],"patient":[159],"(1.4%),":[160,179],"partial":[161],"(PR)":[163],"29":[165],"(40.3%),":[166,272],"stable":[167],"(SD)":[169],"41":[171],"(56.9%),":[172],"(PD)":[176],"resulting":[180],"an":[182],"ORR":[183,207],"41.7%":[185],"a":[187,192,211,304,322],"DCR":[188],"98.6%.":[190],"conservative":[193],"sensitivity":[194],"analysis":[195],"encompassing":[196],"all":[197],"treated":[199],"patients-treating":[200],"13":[202],"non-evaluable":[203],"non-responders-the":[206],"35.3%.":[209],"After":[210],"median":[212,218],"follow-up":[213],"17.2":[215],"months,":[216],"PFS":[219,233],"20.9":[221],"months":[222],"(95%":[223],"CI,":[224],"13.7":[225],"months-not":[226],"reached),":[227],"6-,":[229],"12-,":[230],"24-month":[232],"rates":[234],"84.7%,":[236],"69.6%,":[237],"47.3%,":[239],"respectively.":[240],"Median":[241],"OS":[242,247],"not":[244],"reached,":[245],"data":[248],"remained":[249],"immature.":[250],"most":[252,277],"frequent":[253,278],"any-grade":[254],"adverse":[255],"events":[256],"(AEs)":[257],"were":[258,289],"elevated":[259],"aspartate":[260],"aminotransferase":[261],"(48.6%),":[262],"anemia":[263],"(44.4%),":[264],"lymphopenia":[265],"hypoalbuminemia":[267],"(41.7%":[268],"each),":[269],"hyperglycemia":[271],"neutropenia":[274],"individual":[279],"grade":[280,285],"\u22653":[281,286],"AE":[282],"(5.6%).":[283],"No":[284],"bevacizumab-specific":[287],"toxicities":[288],"observed.":[290],"These":[291],"findings":[292,343],"suggest":[293],"that":[294],"XELOX":[297],"demonstrates":[298],"clinically":[299],"meaningful":[300],"manageable":[305],"profile":[307],"NET":[310],"patients.":[311],"Given":[312],"single-arm":[316],"design,":[317],"may":[320],"represent":[321],"potential":[323],"alternative":[324],"sequential":[326],"option":[328],"when":[329],"alkylating-agent-based":[330],"is":[332],"unsuitable,":[333],"whereas":[334],"prospective":[335],"comparative":[336],"studies":[337],"warranted":[339],"to":[340],"validate":[341],"these":[342],"determine":[345],"optimal":[347],"clinical":[348],"role.":[349]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-10-01T00:00:00"}